编者按：“让天下没有难做的药，难治的病”，是初心，更是愿景。自成立以来，药明康德步履不停：从一间实验室，到覆盖亚洲、欧洲和北美的全球网络。从早期的化学合成服务，到贯穿研究（R）、开发（D）和生产（M）的一体化平台。从第一位客户，到全球三十多个国家的数千合作伙伴。不断发展的，是规模与能力；始终坚守的，是梦想与承诺。
致敬来时路，共谱新篇章！在这一系列访谈中，我们以“逐梦者”视角，回顾药明康德成长发展的峥嵘岁月，回望赋能客户创新的并肩往事，更以独特的“药明精神”展望未来新篇章。
十月的瑞士阳光清朗，清晨的汝拉山被一层薄雾轻柔笼罩，山林间偶尔传来几声清脆的鸟鸣。在这片静谧的山谷中，药明康德库威（Couvet）基地也渐渐苏醒。
就在这份宁静中，基地负责人杰米·安德鲁斯（Jamie Andrews）接收到一封特别的邮件。发送邮件的是一位正在合作的客户，他希望将一批关键临床药物的交付时间提前整整一个月。
留给团队的时间被骤然压缩了一半。
一场跨时区的项目会议迅速召开。来自欧洲与中国的研发、生产、质量、分析等团队在线聚集。杰米在会议中语速平稳却坚定地传达了客户的新需求，同时迅速制订了新的时间表——在宁静的汝拉山山谷里，一场与时间赛跑的竞赛悄然开启。
尽管时间缩短，一切流程却依然有条不紊地展开。在杰米看来，这份从容源自药明康德全球一体化CRDMO平台的自信与底气。
对他而言，这份沉着应对早已成为一种经过岁月打磨的本能——一种根植于他多年制药生涯的肌肉记忆。
从汝拉山到地球村：绘制全球化网络
杰米的职业旅程足迹遍布全球。26年前，他在澳大利亚一家公司担任工程师，此后投身医药行业。随后，他先后辗转英国和爱尔兰，直到2010年定居瑞士。
2021年，杰米加入药明康德瑞士库威基地，为自己的全球化旅程增添了崭新一笔。
在库威，杰米的全球背景以及国际视角，与药明康德的全球化使命相得益彰。
从一间650平方米的实验室起步，经过多年的发展，药明康德在亚洲、欧洲和北美拥有二十多个研发和生产基地。从中国到新加坡，从瑞士到美国，药明康德的CRDMO业务平台如同一张精准编织的“分子地图”，在不同经纬线间协同运转。
其中，坐落在欧洲创新高地的库威基地，在药明康德全球CRDMO赋能平台中扮演着重要角色。立足于当地，这个专注于制剂商业化生产和包装的基地，正为全球多地的客户提供赋能。
如今，药明康德库威基地正在为欧洲、美国、加拿大、日本、澳大利亚和新西兰的客户提供支持，并于近期获得GMP认证，进一步打开巴西和土耳其等新兴市场的大门。
完成“不可能的任务”
谈及全球化合作时，杰米回想起一次印象深刻的经历。
当时，杰米收到了一位客户的请求，对方期望尽快启动一个商业化项目。令客户头疼的是，某些原料在当地的采购周期漫长，按时启动项目几乎是一项不可能完成的任务。
当客户抱着试试看的心态发来邮件时，杰米却显得从容不迫：“凭借药明康德全球运营网络的优势，及时成功采购所有原料并非不可能。”
在团队协调下，项目所需原料很快完成采购并运抵库威。依托药明康德的全球网络，库威基地提前完成了客户“不可能的挑战”，保证了项目的及时启动。
这样的故事，在杰米的记忆中屡见不鲜。
在另一次合作中，得益于与药明康德在上海外高桥和无锡的团队紧密合作，库威基地快速完成技术转移及生产等，助力客户顺利递交了新药申请（NDA）。这些跨区域团队间无缝衔接的合作经历，也让杰米在应对各类客户需求的时候更加信心十足。
在杰米看来，这些高效运转的全球协作，离不开药明康德全球一体化CRDMO模式的支持。而其中的核心理念正是“跟随科学、跟随客户、跟随分子”。
这一理念意味着，基于独特的一体化CRDMO平台，药明康德能够从分子发现之初，陪伴客户一路走到药物上市的终点。
例如，一个项目在药明康德的其他基地完成了早期临床阶段开发后，可以无缝衔接到库威基地，将项目推进到后期临床和商业化生产阶段。这种全周期、一体化的支持，能避免多环节转移带来的时间延误与技术风险。
客户对库威基地的信任，同样离不开药明康德25年来长期坚守的全球质量体系。
2009年以来，药明康德化学业务平台成功通过全球监管机构的审计超过140次，所支持的创新药在全球超过100个国家和地区上市。得益于出色的质量记录，已有25次新药上市批准前检查（PAI，Pre-Approval Inspection）得到美国FDA和EMA豁免。
在药明康德库威基地，全球统一的质量标准体系确保了结果的一致性。在这里生产的产品经过包装，可发往欧洲、北美或亚太的不同地区。
面向未来，持续建设新能力
在药明康德的4年间，杰米亲历了库威基地产能与能力的持续提升。例如，为了满足持续增长的客户需求，库威基地新增了干法制粒、湿法制粒和OEB4高密闭设备等全新的口服固体制剂技术。
“在2024年，我们已经实现了口服制剂产能的翻倍。”杰米介绍道，2025年，库威基地每年可生产多达20亿片药片和2.5亿粒胶囊，包装方面可支持1.5亿个泡罩和1500万瓶药瓶。
库威基地产能与能力拓展的步伐仍在延续。这一切，正是“为未来而建”。
在2025年9月，杰米见证着基地中一座五层新楼的封顶。这是库威基地全新的制剂大楼，配备了喷雾干燥设备（PSD-4），预计将于2026年四季度投入运营，为全球客户提供喷雾干燥能力——一项提升小分子口服吸收能力的关键技术。
未来，库威基地还将进一步拓展赋能平台，包括引入注射剂生产线和脂质纳米粒技术，来满足客户多样化需求。
在挑战中前行
结束会议后，杰米捧起尚有余温的咖啡，望向窗外。周围风景依旧，汝拉山麓绿草如茵，山林间依旧有鸟儿掠过，一切又回归到了开始的宁静。
正如眼前的景象所映照的那样，在全球化赋能创新的过程中，药明康德坚定地承担着企业社会责任，践行可持续发展理念。
在库威基地，屋顶的太阳能电池板每年能提供175兆瓦时的能源，足以为一部手机每天充电，长达5万年。同时，这里的所有废水均经过特殊处理，将对环境产生的影响降到极低；实验室的印刷材料，也通过专业回收，进入下一个生命循环……
这些努力也得到了国际权威评级机构的认可。2024年11月，库威基地获得全球企业社会责任评级专业机构EcoVadis银牌认证，在所有参与评级的公司中排名前9%。
无论是在瑞士库威，还是全球其他基地，可持续发展理念始终贯穿了药明康德的战略与运营。
回到电脑前，杰米又投入到下一位客户的项目中。对他来说，这次挑战是作为库威基地负责人日常工作的一个缩影。在药明康德，挑战并不罕见。它们更像是一场场新的冒险，带来新的经历和突破。
偶尔，杰米也会回想过去的工作。那时，他的整个职业生涯或许只会追随一两个分子的研发到市场化工作。而如今，他的日常是每天都在努力帮助客户将各种分子的开发加速推进，为患者带来更多创新药物。
“这是我真正的动力，早日实现‘让天下没有难做的药，难治的病’的伟大愿景。”杰米说。
At Couvet, Speed has an Address
Editor’s Note: “Every drug can be made and every disease can be treated”. Since 2000, from a single laboratory to a global network spanning Asia, Europe, and North America; from early chemical synthesis services to an integrated platform that connects Research (R), Development (D), and Manufacturing (M); from its very first customer to thousands of partners across more than 30 countries, WuXi AppTec has never stopped moving forward to realize its enduring vision.
In tribute to the journey, we look back through the eyes of our “dream-makers”: revisiting the stories of partnership that empowered global innovation, and the unique spirit that continues to guide us toward the next chapter.
On a crisp, sunny October morning in Couvet, Switzerland, a request comes into Jamie Andrews’ phone: a client needs a critical clinical batch one month earlier than scheduled; the new deadline is in just four weeks.
Within hours, Andrews has quality, analytical, and project teams in Europe and China moving in parallel. As one team drafts protocols, another pulls testing windows forward and untangles the supply paths.
“There’s always a way to get things done,” Andrews says. For the head of WuXi AppTec’s Couvet site, that steady composure is built from a career of hopping hemispheres and stitching together production lines that span continents.
A Global Life, a Global Mandate
Andrews began his career in Australia, trained as an engineer. More than 20 years in pharma took him from Australia to England, Ireland, and finally Switzerland in 2010. He joined WuXi AppTec in 2021, bringing a distinctly international lens, borne from a career spent reading problems from multiple time zones at once.
His global background matters because Couvet’s daily work is international by design. Set in the center of Europe, the site supports clients across Europe, the U.S., Canada, Japan, Australia, New Zealand, and beyond, and has recently added GMP certifications that open doors in markets such as Brazil and Turkey. It is the hub for manufacturing, packaging, and testing late-stage clinical and commercial oral solid drug products, plugged directly into WuXi AppTec’s “follow the molecule” network from discovery to launch. “We enhance supply chain flexibility for our clients, providing a cost-effective option to deliver high-quality drug products to patients worldwide,” Andrews says.
Behind that reach are capacity and capability. “There’s already been significant investment at our site,” Andrews says. In recent years, the site has installed new oral-solid-dosage technologies such as dry granulation, wet granulation, and OEB4 high-containment equipment to support a broader range of client needs.
“Additionally, we have doubled manufacturing and packaging capacities,” he continues. In 2025, the lines can turn out up to 2 billion tablets and 250 million capsules a year, and package 150 million blister packs, plus 15 million bottles annually.
A Global CRDMO for Global Customers
Couvet’s advantage lies in how it operates within WuXi AppTec’s global CRDMO system (Contract Research, Development, and Manufacturing Organization). “Our customers like to work with one company,” Andrews says. “Often, after partnering with other WuXi AppTec teams in early clinical stages, they are ready to commercialize, and that is where our site comes in.” By completing journeys that begin at sister sites around the world, Couvet delivers products through global synergy and a seamless handover.
Andrews points to two moments that show how the network supports clients in complex projects. In one program, a client was preparing a commercial launch of a complex product, and sourcing key materials on time was challenging. Few vendors could deliver within the window.
“By leveraging the strength of our global network, we were able to successfully secure all the materials and keep the project on track.” Andrews said. A team in Shanghai secured the materials quickly, while a project management team streamlined activities in parallel, so no step idled in the middle.
With the support, the Couvet site delivered the results ahead of expectation. “That allowed us to meet the client’s launch schedule and most importantly, deliver the drug products to patients without delay.” Andrews says.
In another example, teams across Shanghai, Wuxi City, and Couvet collaborated closely, quickly aligned the manufacturing process and completed an NDA submission successfully.
According to Andrews, this is why customers increasingly seek partners with a true global footprint, not just a single manufacturing location but multiple qualified sites around the world, so that supply is resilient and secure.
Global Spirit, Locally Established
Serving globally is easier said than done. At Couvet, a single bulk batch can be packaged and released for Europe, North America, or Asia Pacific. A harmonized global quality system keeps outcomes consistent. “We have the same policies, the same procedures, the same document management systems across all our sites to ensure we produce the same high level of quality,” Andrews said, “and, most importantly, to protect patient safety.”
To Andrews, however, global reach does not mean losing sight of local roots. Originally a commercial manufacturing site within a large pharmaceutical company, the Couvet site built a strong quality track record with European authorities and the FDA, and it has maintained excellence in commercial manufacturing.
From Andrews’s window, the Jura Mountains roll away into green grass and forest. Environmental stewardship matters in Switzerland, and it shows in his team’s operations. The site integrates sustainability into daily practice, generating 175 MWh of renewable energy annually from rooftop solar panels, enough to charge a mobile phone every day for 50,000 years. Alongside wastewater treatment and materials recycling, the site earned a Silver EcoVadis medal, placing it in the top 9% of rated companies.
It also stays close to its community, from engaging local suppliers on expansion projects to turning the company Christmas party into a small marketplace where regional artisans and producers were invited to sell their goods. “We are part of an ecosystem here,” Andrews says. “We try to contribute to it.”
Building for What’s Next
The next chapter at Couvet is already framed in scaffolding. Just beyond the packaging halls, crews are installing a commercial PSD-4 spray-drying suite built for the kind of tricky, low-solubility compounds that clients increasingly ask for. The structure is slated to be operational in Q4 2026. Looking further ahead: Andrews’ team is laying the groundwork for parenteral drug-product capabilities, including injectable manufacturing lines and lipid-nanoparticle technologies, so a client can move from tablets and capsules to sterile formats without leaving the WuXi AppTec global enabling platform.
Scale is another multiplier. Having doubled manufacturing and packaging capacity, Couvet can absorb programs with heavier volume profiles and give clients room to ramp a launch, to ride demand spikes, to consolidate supply under one roof.
“One of the things I really appreciate about working at WuXi AppTec is the challenge that comes every day. It's like being on an adventure. I am doing different things every day.” Andrews says. “That's my day-to-day job, bringing innovative products to patients. That's what really motivates me.”
免责声明：本文 仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗 方案指导，请前往正规医院就诊。
版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。
热门跟贴